Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it will invest in a novel scientific approach, called disease interception, to find ways to intercept type 1 diabetes (T1D) using new diagnostic and pre-disease intervention strategies. If successful, this approach has the potential to transform the standard of care in T1D.
This new approach to T1D is the first in a series of disease areas to be tackled as part of Janssen's newly announced Disease Interception Accelerator (DIA), an autonomous incubator-like group that seeks to identify the root causes of disease and enable the development of interventions that stop the progression to disease. Janssen scientists will work to develop new diagnostic, therapeutic or combination approaches for T1D interception by understanding the role of potential triggers and initiating steps on the pathway to T1D.
http://www.marketwatch.com/story/ja...type-1-diabetes-together-with-jdrf-2015-02-12
This new approach to T1D is the first in a series of disease areas to be tackled as part of Janssen's newly announced Disease Interception Accelerator (DIA), an autonomous incubator-like group that seeks to identify the root causes of disease and enable the development of interventions that stop the progression to disease. Janssen scientists will work to develop new diagnostic, therapeutic or combination approaches for T1D interception by understanding the role of potential triggers and initiating steps on the pathway to T1D.
http://www.marketwatch.com/story/ja...type-1-diabetes-together-with-jdrf-2015-02-12